Search results for "Monoamine oxidase B"

showing 7 items of 7 documents

Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors

2018

Monoamine oxidase B (MAO-B) catalyzes deamination of monoamines such as neurotransmitters dopamine and norepinephrine. Accordingly, small-molecule MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression or Parkinson's disease. Coumarin with a functionalized 3-phenyl ring system is a promising scaffold for building potent MAO-B inhibitors. Here, a vast set of 3-phenylcoumarin derivatives was designed using virtual combinatorial chemistry or rationally de novo and synthesized using microwave chemistry. The derivatives inhibited the MAO-B at 100 nM−1 μM. The IC50 value of the most potent derivative 1 was 56 nM. A docking-based structure-activi…

0301 basic medicineentsyymitParkinson's diseaseParkinsonin tautita311101 natural scienceslääkesuunnittelumonoamine oxidase B (MAO-B)lcsh:Chemistry03 medical and health scienceschemistry.chemical_compoundstructure-activity relationship (SAR)Dopamine3-phenylcoumarinmedicineStructure–activity relationshipoksidoreduktaasitkumariinitta116ta317inhibiittoritOriginal Researchchemistry.chemical_classificationbiologyvirtual drug designta1182General ChemistryCoumarin3. Good health0104 chemical sciences010404 medicinal & biomolecular chemistryChemistry030104 developmental biologyMonoamine neurotransmitterEnzymeBiochemistrychemistrylcsh:QD1-999Docking (molecular)biology.proteinParkinson’s diseaseMonoamine oxidase BMonoamine oxidase Amedicine.drugFrontiers in Chemistry
researchProduct

Immuno-fluorescence cytochemistry on thin frozen sections of human substantia nigra for staining of monoamine oxidase A and monoamine oxidase B: a pi…

1990

Immunofluorescence cytochemistry on thin frozen sections of human substantia nigra for staining of MAO-A and MAO-B revealed that only about 10% of the melanin-containing neurons are positive for MAO-A, while they are substantially free of MAO-B.

Frozen section procedurebiologymedicine.diagnostic_testMonoamine oxidaseChemistrySubstantia nigraImmunofluorescenceMolecular biologyStainingnervous systemBiochemistrybiology.proteinmedicineCytochemistrysense organsMonoamine oxidase BMonoamine oxidase A
researchProduct

The Association between a MAOB Variable Number Tandem Repeat Polymorphism and Cocaine and Opiate Addictions in Polyconsumers

2021

Genetic analysis of the association between alcohol, cocaine, and opiate addiction and variable number tandem repeat (VNTR) polymorphisms in monoamine oxidase B (MAOB) and serotonergic 5-hydroxytryptamine (serotonin) receptor 1B and 2C (HTR1B 21 and HTR2C) pathway genes was performed in a sample of 302 polyconsumers. Our genetic association analysis revealed a significant association between a 184 base pair (bp) VNTR polymorphism in the MAOB gene and addiction to cocaine and opiates. This work highlights new genetic marker associations in cocaine and opiate polyconsumer addictions. These data help to clarify and quantify the complex role of genetics in addictive disorders, as well as their …

Geneticsbusiness.industryGeneral NeuroscienceAddictionmedia_common.quotation_subjectGenetic counselingMAOBcocaineopioidsNeurosciences. Biological psychiatry. NeuropsychiatrySerotonergicArticlepolymorphismVariable number tandem repeatGenetic markerPharmacogenomicsmental disordersMedicinegeneticsMonoamine oxidase BOpiatepolydrug usebusinessRC321-571media_common
researchProduct

The Anticonvulsant FCE 26743 is a Selective and Short-acting MAO-B Inhibitor Devoid of Inducing Properties towards Cytochrome P450-dependent Testoste…

1994

Abstract The effects of the potent anticonvulsant FCE 26743 ((S)-2-(4-(3-fluorobenzyloxy)benzylamino)propionamide) on monoamine oxidase (MAO) activity were measured in-vitro and ex-vivo using rat tissue homogenates. In-vitro, FCE 26743 showed potent and selective inhibitory properties towards liver MAO-B, with IC50 values about 10−7  m for MAO-B and higher than 10−5  m for MAO-A. When determined ex-vivo in brain, the ED50 value for the inhibition of MAO-B was 1·1 mg kg−1 (p.o.) 1 h post-dosing, whereas MAO-A remained virtually unaffected after administration of 60 mg kg−1. Similar effects were seen in liver. Following oral administration of 5 mg kg−1 FCE 26743 to rats, brain MAO-B inhibitio…

MaleBenzylaminesMonoamine Oxidase InhibitorsMonoamine oxidaseMetabolite3003 Pharmaceutical Science10050 Institute of Pharmacology and ToxicologyPharmaceutical Science610 Medicine & healthMice Inbred StrainsIn Vitro TechniquesPharmacologyHydroxylationRats Sprague-DawleyHydroxylationMicechemistry.chemical_compoundCytochrome P-450 Enzyme SystemOral administrationmedicineAnimalsTestosteroneED50PharmacologyAlanineDose-Response Relationship DrugbiologyChemistryBrainCytochrome P450Rats3004 PharmacologyLiverMechanism of actionbiology.protein570 Life sciences; biologyAnticonvulsantsMonoamine oxidase Bmedicine.symptomJournal of Pharmacy and Pharmacology
researchProduct

Prevalence of fatigue in Parkinson disease and its clinical correlates

2014

Objective: To assess in a noninterventional setting the prevalence and severity of fatigue in patients with Parkinson disease (PD). Methods: This was a cross-sectional study conducted in Italian patients with PD. Objectives included the evaluation of the current prevalence and severity of fatigue in patients with PD measured using the 16-item Parkinson Fatigue Scale (PFS-16), distressing fatigue (defined as a PFS-16 mean score $3.3), and assessment of its clinical correlates. Results: A total of 402 patients were enrolled and 394 patients completed the PFS-16 questionnaire with a PFS-16 mean (6SD) score of 2.87 6 0.99. Of these, 136 patients (33.8%) reported distressing fatigue (PFS-16 mean…

MaleTime FactorsDiseaseDSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders 4th edition; ICD-10 5 International Classification of Diseases 10th revision; MAO-B 5 monoamine oxidase B; MS 5 multiple sclerosis; PD 5 Parkinson disease; PDQ-39 5 39-item Parkinson’s Disease Questionnaire; PDSS 5 Parkinson’s Disease Sleep Scale; PFS-16 5 16-item Parkinson Fatigue Scale; UPDRS 5 Unified Parkinson’s Disease Rating ScaleSeverity of Illness IndexQuality of life80 and overPrevalencePDSS 5 Parkinson’s Disease Sleep ScaleAge FactorDepression (differential diagnoses)FatigueAged 80 and overDepressionmusculoskeletal neural and ocular physiologyAge FactorsParkinson DiseasePDQ-39 5 39-item Parkinson’s Disease QuestionnaireMiddle AgedItalyPFS-16 5 16-item Parkinson Fatigue ScaleFemaleSettore MED/26 - NeurologiaMS 5 multiple sclerosiPsychologyHumanAdultSleep Wake Disordersmedicine.medical_specialtyPD 5 Parkinson diseasemacromolecular substancesArts and Humanities (miscellaneous)Internal medicinemedicineDistressingHumansIn patientAgedCross-Sectional StudieMAO-B 5 monoamine oxidase BUPDRS 5 Unified Parkinson’s Disease Rating Scalenervous system diseasesAdult; Age Factors; Aged; Aged 80 and over; Cross-Sectional Studies; Depression; Fatigue; Female; Humans; Italy; Male; Middle Aged; Parkinson Disease; Prevalence; Severity of Illness Index; Sleep Wake Disorders; Time Factors; Neurology (clinical); Arts and Humanities (miscellaneous)Cross-Sectional Studiesnervous systemICD-10 5 International Classification of Diseases 10th revisionPhysical therapyNeurology (clinical)DSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders 4th editionSleep Disorder
researchProduct

A monoamine oxidase B gene variant and short-term antidepressant treatment response.

2007

Genetic differences among patients suffering from Major Depression are likely to contribute to interindividual differences in medication treatment response. Thus, the identification of gene variants affecting drug response is needed in order to be able to predict response to psychopharmacological drugs. This study analyzed a possible association of the common A644G single nucleotide polymorphism (SNP) within intron 13 of the monoamine oxidase B (MAOB) gene with antidepressant treatment response. The study population consisted of n = 102 patients with major depression (criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; DSM-IV) participating in a randomized do…

OncologyAdultMalemedicine.medical_specialtyMirtazapineSingle-nucleotide polymorphismMirtazapineMianserinPharmacologyDouble-Blind MethodInternal medicinemedicineHumansMonoamine OxidaseBiological PsychiatryAllelesPharmacologyPsychiatric Status Rating ScalesDepressive Disorder MajorbiologyReverse Transcriptase Polymerase Chain ReactionDNAMiddle AgedMianserinParoxetineAntidepressive AgentsIntronsParoxetineData Interpretation Statisticalbiology.proteinAntidepressantFemaleMonoamine oxidase BMonoamine oxidase APsychologyPharmacogeneticsSelective Serotonin Reuptake Inhibitorsmedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Association study of affective disorders with genetic polymorphisms of monoamine oxidases

2000

Introduction: Monoamine oxidases (MAO) catalyze the oxidative deamination of monoamines like norepinephrine, serotonin and dopamine. The existing MAOs (A and B) have distinct although partially overlapping biological functions and distributions in the brain. MAO A is mainly expressed in catecholaminergic neurons. Thirty-fold differences in enzyme activity of MAO A can be found in cultured cells from different individuals suggesting a genetic determination of enzyme activity. Indeed, a point mutation in the coding region of the gene which creates a restriction site for Fnu4HI alters the activity. Moreover, the pharmacological inhibition of monoamine oxidase A activity is one of the most effe…

Pharmacologymedicine.medical_specialtybiologybusiness.industrymedicine.diseaseGenotype frequencySubstance abusePsychiatry and Mental healthMonoamine neurotransmitterEndocrinologyNeurologyMood disordersInternal medicineGenetic variationmedicinebiology.proteinPharmacology (medical)Neurology (clinical)Monoamine oxidase BAlleleMonoamine oxidase AbusinessBiological PsychiatryEuropean Neuropsychopharmacology
researchProduct